MiNK Therapeutics (INKT) Retained Earnings (2020 - 2026)
MiNK Therapeutics (INKT) posted Retained Earnings of -$159.4 million for Q1 2026, down 22072.27% sequentially from -$718916.0 in Q4 2025, and down 23962.52% YoY from N/an in Q1 2025.
MiNK Therapeutics (INKT) Retained Earnings (2020 - 2026) Analysis & Trends
MiNK Therapeutics has reported Retained Earnings for 7 years, with the latest figure at -$159.4 million in Q1 2026.
- Quarterly Retained Earnings fell 23962.52% year-over-year to -$159.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$159.4 million (down 23962.52% YoY) and the FY2025 annual result came in at -$718916.0, up 99.5% from the prior year.
- Retained Earnings eased to -$159.4 million in Q1 2026 per INKT's latest filing, from -$718916.0 in the prior quarter.
- Over five years, Retained Earnings peaked at -$78276.0 in Q3 2022 and troughed at -$159.4 million in Q1 2026.
- A 5-year average of -$58.8 million and a median of -$719318.0 in 2025 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2022 and 2024: Retained Earnings jumped 99.9% in 2022, then slumped 33356.95% in 2024.
- Over 5 years, Retained Earnings stood at -$110.9 million in 2022, then soared by 99.61% to -$430947.0 in 2023, then plunged by 33356.95% to -$144.2 million in 2024, then jumped by 99.5% to -$718916.0 in 2025, then slumped by 22072.27% to -$159.4 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered -$159.4 million, -$718916.0, and -$154.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | 4.38 Bn |
| 10 | MiNK Therapeutics | 59.48 Mn | 59.48 Mn | - | -162.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -162.55 Mn |
| Mar 31, 2026 | -159.40 Mn |
| Dec 31, 2025 | -718,916.00 |
| Sep 30, 2025 | -154.10 Mn |
| Jun 30, 2025 | -719,318.00 |
| Mar 31, 2025 | -662,441.00 |
| Dec 31, 2024 | -144.18 Mn |
| Sep 30, 2024 | -672,838.00 |
| Jun 30, 2024 | -611,375.00 |
| Mar 31, 2024 | -385,780.00 |
| Dec 31, 2023 | -430,947.00 |
| Sep 30, 2023 | -313,188.00 |
| Jun 30, 2023 | -122.82 Mn |
| Mar 31, 2023 | -116.60 Mn |
| Dec 31, 2022 | -110.94 Mn |
| Sep 30, 2022 | -78,276.00 |
| Jun 30, 2022 | -96.84 Mn |
| Mar 31, 2022 | -90.72 Mn |
| Dec 31, 2021 | -625,269.00 |
| Sep 30, 2021 | -77.20 Mn |